Study designs of evaluations included in the review
Randomised controlled trials (RCTs) were eligible for inclusion.
Specific interventions included in the review
Studies that compared oral domperidone given for at least one week with either placebo or a nonsurgical treatment (other drugs, dietary measures or positioning) were eligible for inclusion. The included studies compared domperidone alone (0.3 or 0.6 mg/kg three times daily or before meals) versus placebo or metoclopramide (0.3 mg/kg). The studies were between 2 and 8 weeks in duration.
Participants included in the review
Studies in children (aged younger than 18 years) with a probable diagnosis of GOR (using any definition) were eligible for inclusion. In the included studies, the children were aged from 3 weeks to 11 years. GOR was diagnosed clinically, radiologically and by pH-meter; two studies made the diagnosis using clinical assessment alone.
Outcomes assessed in the review
Studies were eligible if they assessed any of the following primary outcomes: symptoms or change in symptoms of GOR (regurgitation, crying, irritability, vomiting or gagging), adverse effects, clinical complications of GOR, or weight change. GOR symptoms or changes in symptoms were assessed subjectively by the child's parent and/or the treating physician or other investigator. The secondary outcomes reported in the review were: episodes of reflux measured by extended oesophageal pH monitoring; lower oesophageal sphincter pressure measured by oesophageal manometry; and histological evidence of oesophagitis on biopsy.
How were decisions on the relevance of primary studies made?
At least two reviewers selected studies independently. The methods used to resolve any disagreements were not reported.